Gilead
12 Apr 2022
GILEAD BREAST
NCT04958785
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer
Gilead Sciences
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2021-12-14 |
Anticipated End Date | 2024-08-01 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead |
admin@cancerresearchsa.com.au | |
Phone | 08 8359 2565 |
Principal Investigator | A/Prof Rohit Joshi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs